Back to Cardiology
Cardiologyv2016Evidence-Based

Grogan Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Classifies prognosis of patients with wild-type transthyretin amyloid cardiomyopathy using cardiac biomarkers NT-proBNP and troponin T

Clinical Input Parameters

pg/mL
Range: 0 — 50000 pg/mL
ng/mL
Range: 0 — 5 ng/mL
Clinical Assessment
Awaiting Parameters
grogan stage
—stage
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Grogan Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within cardiology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Stage I: NT-proBNP ≤3000 pg/mL AND Troponin T ≤0.05 ng/mL; Stage II: One biomarker above threshold; Stage III: Both biomarkers above threshold

Clinical Pearls & Practice Notes

  • Specifically validated for wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM)
  • Should be used in conjunction with clinical assessment and imaging findings
  • Regular reassessment recommended as biomarkers may change with disease progression or treatment
  • Consider advanced heart failure therapies in Stage III patients
  • Disease-modifying therapies (tafamidis, diflunisal) may be most beneficial in earlier stages
  • Multidisciplinary team approach recommended for optimal management
  • Biomarker thresholds: NT-proBNP >3000 pg/mL and Troponin T >0.05 ng/mL

Evidence & Literature Citations

  1. Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014-1020. doi: 10.1016/j.jacc.2016.06.033
  2. Cappelli F, Baldasseroni S, Bergesio F, et al. Biomarker-based staging system for cardiac transthyretin-related amyloidosis. Eur J Heart Fail. 2020;22(11):2187-2196. doi: 10.1002/ejhf.1898
  3. Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161-172. doi: 10.1016/j.jacc.2016.03.596

Score Interpretation Ranges

Stage I≤ pts

Best prognosis

Stage II≤ pts

Intermediate prognosis

Stage III≤ pts

Poor prognosis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.